Group 1 - The core product ABSK021 of He Yu-B (02256) has received NDA approval for treating symptomatic adult tenosynovial giant cell tumor (TGCT) patients, marking a significant milestone for the company [1] - The FDA has officially accepted the NDA for ABSK021 for systemic treatment of TGCT patients, indicating progress in regulatory approvals [1] - According to Zhongtai Securities, this event signifies the transition of He Yu Pharmaceutical from clinical research to commercialization, validating its full-cycle innovation capability from development to market [1] Group 2 - Long-term follow-up data shows that the response rate of ABSK021 continues to improve over time, suggesting its potential effectiveness [1] - The collaboration with Merck for commercialization is expected to provide stable cash flow for the company [1]
港股异动 | 和誉-B(02256)午后涨超6% ABSK021有望中美上市 公司正式进入商业化阶段